NASDAQ:SRTA
Strata Critical Medical, Inc.
Strata Critical Medical, Inc.'s revenue grew 34.3% in fiscal 2025 to $197.1M while operating margin rose to −11.3%, its highest in 4 years. Free cash flow was −$58.5M, −29.7% of revenue, and the diluted share count rose 5.9%.Summary generated from Strata Critical Medical, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$197.1M
Revenue growth+34.3%
Revenue, 5-yr CAGRn/a
Gross margin20.9%
Operating margin−11.3%
Net margin21.0%
ROICn/a
Return on equity16.5%
Debt / equityn/a
Free cash flow−$58.5M
FCF margin−29.7%
Share count change+5.9%
Financials
| Item | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 146 | 225 | 147 | 197 |
| Operating income | −1 | −54 | −68 | −23 | −22 |
| Net income | −21 | −27 | −56 | −27 | 41 |
| Free cash flow | n/a | −38 | −34 | −33 | −59 |
Recent filings
- 4Insider transaction report
Sep 25, 2026 - 4Insider transaction report
Sep 25, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KResults of a shareholder vote
Jun 3, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - DEF 14AProxy statement
Apr 14, 2026